Brain


Journal

European journal of nuclear medicine and molecular imaging
ISSN: 1619-7089
Titre abrégé: Eur J Nucl Med Mol Imaging
Pays: Germany
ID NLM: 101140988

Informations de publication

Date de publication:
11 2021
Historique:
received: 02 12 2020
accepted: 02 03 2021
pubmed: 8 3 2021
medline: 21 10 2021
entrez: 7 3 2021
Statut: ppublish

Résumé

To consolidate current understanding of detection sensitivity of brain A systematic and exhaustive search of data available in the literature was performed by querying the PubMed/MEDLINE and Cochrane databases for the search terms: ((PET) OR (positron emission tomography)) AND ((FDG) OR (fluorodeoxyglucose)) AND ((encephalitis) OR (brain inflammation)). Studies had to satisfy the following criteria: (i) include at least ten pediatric or adult patients suspected or diagnosed with autoimmune encephalitis according to the current recommendations, (ii) specifically present The search strategy identified 626 articles including references from publications. The detection sensitivity of Brain

Identifiants

pubmed: 33677643
doi: 10.1007/s00259-021-05299-y
pii: 10.1007/s00259-021-05299-y
doi:

Substances chimiques

Radiopharmaceuticals 0
Fluorodeoxyglucose F18 0Z5B2CJX4D

Types de publication

Journal Article Meta-Analysis Review Systematic Review

Langues

eng

Sous-ensembles de citation

IM

Pagination

3847-3858

Informations de copyright

© 2021. The Author(s), under exclusive licence to Springer-Verlag GmbH Germany, part of Springer Nature.

Références

Graus F, Titulaer MJ, Balu R, et al. A clinical approach to diagnosis of autoimmune encephalitis. Lancet Neurol. 2016;15(4):391–404. https://doi.org/10.1016/S1474-4422(15)00401-9 .
doi: 10.1016/S1474-4422(15)00401-9 pubmed: 26906964 pmcid: 5066574
Jmor F, Emsley HC, Fischer M, Solomon T, Lewthwaite P. The incidence of acute encephalitis syndrome in Western industrialised and tropical countries. Virol J. 2008;5(1):134. https://doi.org/10.1186/1743-422X-5-134 .
doi: 10.1186/1743-422X-5-134 pubmed: 18973679 pmcid: 2583971
Titulaer MJ, McCracken L, Gabilondo I, et al. Treatment and prognostic factors for long-term outcome in patients with anti-NMDA receptor encephalitis: an observational cohort study. Lancet Neurol. 2013;12(2):157–65. https://doi.org/10.1016/S1474-4422(12)70310-1 .
doi: 10.1016/S1474-4422(12)70310-1 pubmed: 23290630 pmcid: 3563251
Granerod J, Ambrose HE, Davies NW, et al. Causes of encephalitis and differences in their clinical presentations in England: a multicentre, population-based prospective study. Lancet Infect Dis. 2010;10(12):835–44. https://doi.org/10.1016/S1473-3099(10)70222-X .
doi: 10.1016/S1473-3099(10)70222-X pubmed: 20952256
Mailles A, Stahl J. Infectious encephalitis in France in 2007: a national prospective study. Clin Infect Dis. 2009;49(12):1838–47. https://doi.org/10.1086/648419 .
doi: 10.1086/648419 pubmed: 19929384
Cózar Santiago MDP, Sanchez Jurado R, Sanz Llorens R, Aguilar Barrios JE, Ferrer Rebolleda J. Limbic encephalitis diagnosed With 18F-FDG PET/CT. Clin Nucl Med. 2016;41(2):e101–3. https://doi.org/10.1097/RLU.0000000000001076 .
doi: 10.1097/RLU.0000000000001076
Lancaster E, Martinez-Hernandez E, Dalmau J. Encephalitis and antibodies to synaptic and neuronal cell surface proteins. Neurology. 2011;77(2):179–89. https://doi.org/10.1212/WNL.0b013e318224afde .
doi: 10.1212/WNL.0b013e318224afde pubmed: 21747075 pmcid: 3140073
Rosenfeld MR, Dalmau J. Paraneoplastic neurologic disorders: a brief overview. Memo. 2012;5(3):197–200. https://doi.org/10.1007/s12254-012-0034-z .
doi: 10.1007/s12254-012-0034-z pubmed: 23264806 pmcid: 3525357
McKeon A. Paraneoplastic and other autoimmune disorders of the central nervous system. Neurohospitalist. 2013;3(2):53–64. https://doi.org/10.1177/1941874412453339 .
doi: 10.1177/1941874412453339 pubmed: 23983888 pmcid: 3726118
Dutra LA, Abrantes F, Toso FF, Pedroso JL, Barsottini OGP, Hoftberger R. Autoimmune encephalitis: a review of diagnosis and treatment. Arq Neuropsiquiatr. 2018;76(1):41–9. https://doi.org/10.1590/0004-282X20170176 .
doi: 10.1590/0004-282X20170176 pubmed: 29364393
Darnell RB, Posner JB. Paraneoplastic syndromes involving the nervous system. N Engl J Med. 2003;349(16):1543–54. https://doi.org/10.1056/NEJMra023009 .
doi: 10.1056/NEJMra023009 pubmed: 14561798
Armangue T, Leypoldt F, Dalmau J. Autoimmune encephalitis as differential diagnosis of infectious encephalitis. Curr Opin Neurol. 2014;27(3):361–8. https://doi.org/10.1097/WCO.0000000000000087 .
doi: 10.1097/WCO.0000000000000087 pubmed: 24792345 pmcid: 4132825
Heine J, Prüss H, Bartsch T, Ploner CJ, Paul F, Finke C. Imaging of autoimmune encephalitis--relevance for clinical practice and hippocampal function. Neuroscience. 2015;309:68–83. https://doi.org/10.1016/j.neuroscience.2015.05.037 .
doi: 10.1016/j.neuroscience.2015.05.037 pubmed: 26012492
Diaz-Arias LA, Pardo CA, Probasco JC. Autoimmune encephalitis in the intensive care unit. In: Nelson SE, Nyquist PA, eds. Neurointensive Care Unit. Current Clinical Neurology. Springer International Publishing; 2020:249–263. https://doi.org/10.1007/978-3-030-36548-6_17 .
Guerin J, Watson RE, Carr CM, Liebo GB, Kotsenas AL. Autoimmune epilepsy: findings on MRI and FDG-PET. Br J Radiol. 2019;92(1093). https://doi.org/10.1259/bjr.20170869 .
Kyritsis AP, Markoula S, Alexiou G, et al. Diagnosis and treatment of limbic encephalitis in the cancer patient. Future Oncol Published online June 8, 2020. https://doi.org/10.2217/fon-2020-0080 .
Wang H, Xiao Z. Current progress on assessing the prognosis for anti-N-methyl-D-aspartate receptor (NMDAR) encephalitis. Biomed Res Int. 2020;2020:7506590. https://doi.org/10.1155/2020/7506590 .
doi: 10.1155/2020/7506590 pubmed: 32352007 pmcid: 7178504
Husari KS, Dubey D. Autoimmune epilepsy. Neurotherapeutics. 2019;16(3):685–702. https://doi.org/10.1007/s13311-019-00750-3 .
doi: 10.1007/s13311-019-00750-3 pubmed: 31240596 pmcid: 6694338
Bacchi S, Franke K, Wewegama D, Needham E, Patel S, Menon D. Magnetic resonance imaging and positron emission tomography in anti-NMDA receptor encephalitis: a systematic review. J Clin Neurosci. 2018;52:54–9. https://doi.org/10.1016/j.jocn.2018.03.026 .
doi: 10.1016/j.jocn.2018.03.026 pubmed: 29605275
Dalmau J, Geis C, Graus F. Autoantibodies to synaptic receptors and neuronal cell surface proteins in autoimmune diseases of the central nervous system. Physiol Rev. 2017;97(2):839–87. https://doi.org/10.1152/physrev.00010.2016 .
doi: 10.1152/physrev.00010.2016 pubmed: 28298428 pmcid: 5539405
Arbizu J, Giuliani A, Gállego Perez-Larraya J, et al. Emerging clinical issues and multivariate analyses in PET investigations. Q J Nucl Med Mol Imaging. 2017;61(4):386–404. https://doi.org/10.23736/S1824-4785.17.03024-2 .
doi: 10.23736/S1824-4785.17.03024-2 pubmed: 28750498
Venkatraman A, Opal P. Paraneoplastic cerebellar degeneration with anti-Yo antibodies – a review. Ann Clin Transl Neurol. 2016;3(8):655–63. https://doi.org/10.1002/acn3.328 .
doi: 10.1002/acn3.328 pubmed: 27606347 pmcid: 4999597
Lim M, Gorman M. Autoimmune neurologic disorders in children. Handb Clin Neurol. 2016;133:485–510. https://doi.org/10.1016/B978-0-444-63432-0.00026-8 .
doi: 10.1016/B978-0-444-63432-0.00026-8 pubmed: 27112693
Quartuccio N, Caobelli F, Evangelista L, et al. The role of PET/CT in the evaluation of patients affected by limbic encephalitis: a systematic review of the literature. J Neuroimmunol. 2015;284:44–8. https://doi.org/10.1016/j.jneuroim.2015.05.002 .
doi: 10.1016/j.jneuroim.2015.05.002 pubmed: 26025057
Lee S-W, Park M, Lee S-K, Park Y-B. The efficacy of brain F-fluorodeoxyglucose positron emission tomography in neuropsychiatric lupus patients with normal brain magnetic resonance imaging findings. Lupus. 2012;21(14):1531–7. https://doi.org/10.1177/0961203312459104 .
doi: 10.1177/0961203312459104 pubmed: 22941565
McInnes MDF, Moher D, Thombs BD, et al. Preferred reporting items for a systematic review and meta-analysis of diagnostic test accuracy studies: the PRISMA-DTA statement. JAMA. 2018;319(4):388–96. https://doi.org/10.1001/jama.2017.19163 .
doi: 10.1001/jama.2017.19163 pubmed: 29362800
Whiting PF, Rutjes AWS, Westwood ME, et al. QUADAS-2: a revised tool for the quality assessment of diagnostic accuracy studies. Ann Intern Med. 2011;155(8):529–36. https://doi.org/10.7326/0003-4819-155-8-201110180-00009 .
doi: 10.7326/0003-4819-155-8-201110180-00009 pubmed: 22007046
Kerik-Rotenberg N, Diaz-Meneses I, Hernandez-Ramirez R, et al. A metabolic brain pattern associated with anti-N-methyl-D-aspartate receptor encephalitis. Psychosomatics. 2020;61(1):39–48. https://doi.org/10.1016/j.psym.2019.08.007 .
doi: 10.1016/j.psym.2019.08.007 pubmed: 31611047
Turpin S, Martineau P, Levasseur M-A, et al. 18F-Flurodeoxyglucose positron emission tomography with computed tomography (FDG PET/CT) findings in children with encephalitis and comparison to conventional imaging. Eur J Nucl Med Mol Imaging. 2019;46(6):1309–24. https://doi.org/10.1007/s00259-019-04302-x .
doi: 10.1007/s00259-019-04302-x pubmed: 30863933
Schubert J, Brämer D, Huttner HB, et al. Management and prognostic markers in patients with autoimmune encephalitis requiring ICU treatment. Neurol Neuroimmunol Neuroinflamm. 2018;6(1). https://doi.org/10.1212/NXI.0000000000000514 .
Probasco JC, Solnes L, Nalluri A, et al. Abnormal brain metabolism on FDG-PET/CT is a common early finding in autoimmune encephalitis. Neurol Neuroimmunol Neuroinflamm. 2017;4(4):e352. https://doi.org/10.1212/NXI.0000000000000352 .
doi: 10.1212/NXI.0000000000000352 pubmed: 28567435 pmcid: 5442608
Fiorella DJ, Provenzale JM, Coleman RE, Crain BJ, Al-Sugair AA. (18)F-fluorodeoxyglucose positron emission tomography and MR imaging findings in Rasmussen encephalitis. AJNR Am J Neuroradiol. 2001;22(7):1291–9.
pubmed: 11498416 pmcid: 7975219
Malter MP, Helmstaedter C, Urbach H, Vincent A, Bien CG. Antibodies to glutamic acid decarboxylase define a form of limbic encephalitis. Ann Neurol. 2010;67(4):470–8. https://doi.org/10.1002/ana.21917 .
doi: 10.1002/ana.21917 pubmed: 20437582
Aupy J, Collongues N, Blanc F, Tranchant C, Hirsch E, De Seze J. Encéphalites dysimmunitaires, données cliniques, radiologiques et immunologiques. Rev Neurol. 2013;169(2):142–53. https://doi.org/10.1016/j.neurol.2012.05.014 .
doi: 10.1016/j.neurol.2012.05.014 pubmed: 23099105
Baumgartner A, Rauer S, Mader I, Meyer PT. Cerebral FDG-PET and MRI findings in autoimmune limbic encephalitis: correlation with autoantibody types. J Neurol. 2013;260(11):2744–53. https://doi.org/10.1007/s00415-013-7048-2 .
doi: 10.1007/s00415-013-7048-2 pubmed: 23900756
Shin Y-W, Lee S-T, Shin J-W, et al. VGKC-complex/LGI1-antibody encephalitis: clinical manifestations and response to immunotherapy. J Neuroimmunol. 2013;265(1–2):75–81. https://doi.org/10.1016/j.jneuroim.2013.10.005 .
doi: 10.1016/j.jneuroim.2013.10.005 pubmed: 24176648
Masangkay N, Basu S, Moghbel M, Kwee T, Alavi A. Brain 18F-FDG-PET characteristics in patients with paraneoplastic neurological syndrome and its correlation with clinical and MRI findings. Nucl Med Commun. 2014;35(10):1038–46. https://doi.org/10.1097/MNM.0000000000000163 .
doi: 10.1097/MNM.0000000000000163 pubmed: 25023997
Wegner F, Wilke F, Raab P, et al. Anti-leucine rich glioma inactivated 1 protein and anti-N-methyl-D-aspartate receptor encephalitis show distinct patterns of brain glucose metabolism in 18F-fluoro-2-deoxy-d-glucose positron emission tomography. BMC Neurol. 2014;14(1):136. https://doi.org/10.1186/1471-2377-14-136 .
doi: 10.1186/1471-2377-14-136 pubmed: 24950993 pmcid: 4076767
Flanagan EP, Kotsenas AL, Britton JW, et al. Basal ganglia T1 hyperintensity in LGI1-autoantibody faciobrachial dystonic seizures. Neurol Neuroimmunol Neuroinflamm. 2015;2(6). https://doi.org/10.1212/NXI.0000000000000161 .
Solnes LB, Jones KM, Rowe SP, et al. Diagnostic value of 18 F-FDG PET/CT versus MRI in the setting of antibody-specific autoimmune encephalitis. J Nucl Med. 2017;58(8):1307–13. https://doi.org/10.2967/jnumed.116.184333 .
doi: 10.2967/jnumed.116.184333 pubmed: 28209905 pmcid: 6944181
Jang Y, Lee S-T, Bae J-Y, et al. LGI1 expression and human brain asymmetry: insights from patients with LGI1-antibody encephalitis. J Neuroinflammation. 2018;15. https://doi.org/10.1186/s12974-018-1314-2 .
Steriade C, Moosa ANV, Hantus S, Prayson RA, Alexopoulos A, Rae-Grant A. Electroclinical features of seizures associated with autoimmune encephalitis. Seizure. 2018;60:198–204. https://doi.org/10.1016/j.seizure.2018.06.021 .
doi: 10.1016/j.seizure.2018.06.021 pubmed: 30031297
Tripathi M, Tripathi M, Roy SG, et al. Metabolic topography of autoimmune non-paraneoplastic encephalitis. Neuroradiology. 2018;60(2):189–98. https://doi.org/10.1007/s00234-017-1956-2 .
doi: 10.1007/s00234-017-1956-2 pubmed: 29255919
Falip M, Rodriguez-Bel L, Castañer S, et al. Hippocampus and insula are targets in epileptic patients with glutamic acid decarboxylase antibodies. Front Neurol. 2018;9:1143. https://doi.org/10.3389/fneur.2018.01143 .
doi: 10.3389/fneur.2018.01143 pubmed: 30687213
Lv R-J, Pan J, Zhou G, et al. Semi-quantitative FDG-PET analysis increases the sensitivity compared with visual analysis in the diagnosis of autoimmune encephalitis. Front Neurol. 2019;10:576. https://doi.org/10.3389/fneur.2019.00576 .
doi: 10.3389/fneur.2019.00576 pubmed: 31244751 pmcid: 6563773
Strohm T, Steriade C, Wu G, Hantus S, Rae-Grant A, Larvie M. FDG-PET and MRI in the evolution of new-onset refractory status Epilepticus. Am J Neuroradiol. 2019;40(2):238–44. https://doi.org/10.3174/ajnr.A5929 .
doi: 10.3174/ajnr.A5929 pubmed: 30679215 pmcid: 7028610
Deuschl C, Rüber T, Ernst L, et al. 18F-FDG-PET/MRI in the diagnostic work-up of limbic encephalitis. Treglia G, ed. PLoS One. 2020;15(1):e0227906. https://doi.org/10.1371/journal.pone.0227906 .
doi: 10.1371/journal.pone.0227906 pubmed: 31951636 pmcid: 6968877
Liu X, Shan W, Zhao X, et al. The clinical value of 18F-FDG-PET in autoimmune encephalitis associated with LGI1 antibody. Front Neurol. 2020;11:418. https://doi.org/10.3389/fneur.2020.00418 .
doi: 10.3389/fneur.2020.00418 pubmed: 32581996 pmcid: 7290050
Graus F. Recommended diagnostic criteria for paraneoplastic neurological syndromes. J Neurol Neurosurg Psychiatry. 2004;75(8):1135–40. https://doi.org/10.1136/jnnp.2003.034447 .
doi: 10.1136/jnnp.2003.034447 pubmed: 15258215 pmcid: 1739186
Venkatesan A, Adatia K. Anti-NMDA-receptor encephalitis: from bench to clinic. ACS Chem Neurosci. 2017;8(12):2586–95. https://doi.org/10.1021/acschemneuro.7b00319 .
doi: 10.1021/acschemneuro.7b00319 pubmed: 29077387
Leypoldt F, Armangue T, Dalmau J. Autoimmune encephalopathies: autoimmune encephalopathies. Ann N Y Acad Sci. 2015;1338(1):94–114. https://doi.org/10.1111/nyas.12553 .
doi: 10.1111/nyas.12553 pubmed: 25315420
Najjar S, Steiner J, Najjar A, Bechter K. A clinical approach to new-onset psychosis associated with immune dysregulation: the concept of autoimmune psychosis. J Neuroinflammation. 2018;15. https://doi.org/10.1186/s12974-018-1067-y .
Staley EM, Jamy R, Phan AQ, Figge DA, Pham HP. N -methyl- D -aspartate receptor antibody encephalitis: a concise review of the disorder, diagnosis, and management. ACS Chem Neurosci. 2019;10(1):132–42. https://doi.org/10.1021/acschemneuro.8b00304 .
doi: 10.1021/acschemneuro.8b00304 pubmed: 30134661
Probasco JC, Solnes L, Nalluri A, et al. Decreased occipital lobe metabolism by FDG-PET/CT: an anti-NMDA receptor encephalitis biomarker. Neurol Neuroimmunol Neuroinflamm. 2018;5(1):e413. https://doi.org/10.1212/NXI.0000000000000413 .
doi: 10.1212/NXI.0000000000000413 pubmed: 29159205
Goudot M, Frismand S, Hopes L, et al. GAD65-Ab encephalitis and subtle focal status epilepticus. Epileptic Disord. 2019;21(5):437–42. https://doi.org/10.1684/epd.2019.1094 .
doi: 10.1684/epd.2019.1094 pubmed: 31649008
Varadkar S, Bien CG, Kruse CA, et al. Rasmussen’s encephalitis: clinical features, pathobiology, and treatment advances. Lancet Neurol. 2014;13(2):195–205. https://doi.org/10.1016/S1474-4422(13)70260-6 .
doi: 10.1016/S1474-4422(13)70260-6 pubmed: 24457189 pmcid: 4005780
Dalmau J, Lancaster E, Martinez-Hernandez E, Rosenfeld MR, Balice-Gordon R. Clinical experience and laboratory investigations in patients with anti-NMDAR encephalitis. Lancet Neurol. 2011;10(1):63–74. https://doi.org/10.1016/S1474-4422(10)70253-2 .
doi: 10.1016/S1474-4422(10)70253-2 pubmed: 21163445 pmcid: 3158385
Nobili F, Arbizu J, Bouwman F, et al. European Association of Nuclear Medicine and European Academy of Neurology recommendations for the use of brain 18 F-fluorodeoxyglucose positron emission tomography in neurodegenerative cognitive impairment and dementia: Delphi consensus. Eur J Neurol. 2018;25(10):1201–17. https://doi.org/10.1111/ene.13728 .
doi: 10.1111/ene.13728 pubmed: 29932266
Hansen N, Widman G, Stuff S, et al. Cancer frequency detected by positron emission tomography-computed tomography in limbic encephalitis. Epilepsy Behav. 2018;89:105–11. https://doi.org/10.1016/j.yebeh.2018.09.043 .
doi: 10.1016/j.yebeh.2018.09.043 pubmed: 30408704
Kampe KKW, Rotermund R, Tienken M, et al. Diagnostic value of positron emission tomography combined with computed tomography for evaluating critically ill neurological patients. Front Neurol. 2017;8. https://doi.org/10.3389/fneur.2017.00033 .
Leypoldt F, Buchert R, Kleiter I, et al. Fluorodeoxyglucose positron emission tomography in anti-N-methyl-D-aspartate receptor encephalitis: distinct pattern of disease. J Neurol Neurosurg Psychiatry. 2012;83(7):681–6. https://doi.org/10.1136/jnnp-2011-301969 .
doi: 10.1136/jnnp-2011-301969 pubmed: 22566598
Verger A, Lagarde S, Maillard L, Bartolomei F, Guedj E. Brain molecular imaging in pharmacoresistant focal epilepsy: current practice and perspectives. Rev Neurol (Paris). Published online June 5, 2017. https://doi.org/10.1016/j.neurol.2017.05.001 .

Auteurs

Manon Bordonne (M)

Department of Nuclear Medicine and Nancyclotep Imaging Platform, Université de Lorraine, CHRU Nancy, Rue du Morvan, 54500 Vandoeuvre-les-Nancy, F-54000, Nancy, France.

Mohammad B Chawki (MB)

Department of Nuclear Medicine and Nancyclotep Imaging Platform, Université de Lorraine, CHRU Nancy, Rue du Morvan, 54500 Vandoeuvre-les-Nancy, F-54000, Nancy, France.

Matthieu Doyen (M)

Department of Nuclear Medicine and Nancyclotep Imaging Platform, Université de Lorraine, CHRU Nancy, Rue du Morvan, 54500 Vandoeuvre-les-Nancy, F-54000, Nancy, France.
Université de Lorraine, IADI, INSERM U1254, F-54000, Nancy, France.

Aurelie Kas (A)

Nuclear Medicine Department, Pitié-Salpêtrière Hospital, APHP Sorbonne-Université, Laboratoire d'Imagerie Biomédicale, Sorbonne Université, F-75000, Paris, France.

Eric Guedj (E)

Nuclear Medicine Department, Aix Marseille Univ, APHM, CNRS, Centrale Marseille, Institut Fresnel, Timone Hospital, CERIMED, F-13000, Marseille, France.

Louise Tyvaert (L)

Department of Neurology, Université de Lorraine, CRAN UMR 7039, CHRU, F-54000, Nancy, France.

Antoine Verger (A)

Department of Nuclear Medicine and Nancyclotep Imaging Platform, Université de Lorraine, CHRU Nancy, Rue du Morvan, 54500 Vandoeuvre-les-Nancy, F-54000, Nancy, France. a.verger@chru-nancy.fr.
Université de Lorraine, IADI, INSERM U1254, F-54000, Nancy, France. a.verger@chru-nancy.fr.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH